Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer

Neoplasia

Volumn 8, Issue 4, 2006, Pages 268-278

  Kwong, Joseph ^a   Lee, Ji Young ^a   Wong, Kwong Kwok ^b   Zhou, Xiaofeng ^c   Wong, David T W ^c   Lo, Kwok Wai ^d   Welch, William R ^a   Berkowitz, Ross S ^a   Mok, Samuel C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chromosome 3p22.3; DLEC1; Epithelial ovarian cancer; Histone hypoacetylation; Promoter hypermethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHROMOSOME 3P; COLONY FORMATION; CONTROLLED STUDY; DLEC1 GENE; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 33646434223     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05502     Document Type: Article

References (33)

1. Greenlee RT, Murray T, Bolden S, and Wingo PA (2000). Cancer statistics. CA Cancer J Clin 50, 7-33.
2. Skolnick MH, Frank T, Shattuck-Eidens D, and Tavtigian S (1997). Genetic susceptibility to breast and ovarian cancer. Pathol Biol (Paris) 45, 245-249.
3. Angioli R, Estape R, Mason M, and Penalver M (1998). Hereditary and sporadic ovarian cancer: genetic testing and clinical implications. Int J Oncol 12, 1029-1034.
4. Zabarovsky ER, Lerman MI, and Minna JD (2002). Tumor suppressors on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21, 6915-6935.
5. Leary JA, Doris CP, Boltz EM, Houghton CR, Kefford RF, and Friedkander ML (1993). Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer. Int J Gynecol Cancer 3, 293-298.
6. Jones MH and Nakamura Y (1992). Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene 7, 1631-1634.
7. Lounis H, Mes-Masson A-M, Dion F, Bradley WEC, Seymour RJ, Provencher D, and Tonin PN (1998). Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene 17, 2359-2365.
8. Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, Broggini M, Morelli C, Barbanti-Brodano G, Maher ER, and Latif F (1999). Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 59, 4662-4667.
9. Rimessi P, Gualandi F, Morelli C, Trabanelli C, Wu Q, Possati L, Montesi M, Barrett JC, and Barbanti-Brodano G (1994). Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions in 3p involved in ovarian cancer. Oncogene 9, 3467-3474.
10. Foster K, Osborne RJ, Huddart RA, Affara NA, Ferguson-Smith MA, and Maher ER (1995). Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumor suppressor gene in gonadal tumors. Eur J Cancer 31A, 2392-2395.
11. Buttitta F, Marchetti A, Radi O, Bertacca G, Pellegrini S, Gadducci A, Genazzani AR, and Bevilacqua G (1998). Evaluation of FHIT gene alterations in ovarian cancer. Br J Cancer 77, 1048-1051.
12. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, et al. (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene 20, 1509-1518.
13. Yoon JH, Dammann R, and Pfeifer GP (2001). Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinoma. Int J Cancer 94, 212-217.
14. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, and Gazdar AF (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8, 3324-3331.
15. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, and Nakamura Y (1999). Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res 59, 1966-1972.
16. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, and Berkowitz RS (1995). Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 218, 499-507.
17. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408.
18. Zhou X, Mok SC, Chen Z, Li Y, and Wong DTW (2004). Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 115, 327-330.
19. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699-702.
20. Ginzinger DG, Godfrey TE, Nigro J, Moore DH II, Suzuki S, Pallavicini MG, Gray JW, and Jensen RH (2000). Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 60, 5405-5409.
21. Wang TL, Maierhofer C, Speicher MR, Lengauer C, Vogelstein B, Kinzler KW, and Velculescu VE (2002). Digital karyotyping. Proc Natl Acad Sci USA 99, 16156-16161.
22. Herman JG and Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042-2054.
23. Senchenko V, Liu J, Braga E, Mazurenko N, Loginov W, Seryogin Y, Bazov I, Protopopov A, Kisseljov FL, Kashuba V, et al. (2003). Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene 22, 2984-2992.
24. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, Ermilova V, Kazubskaya T, Garkavtseva R, Zabarovska VI, et al. (2004). Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23, 5719-5728.
25. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, et al. (2004). Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155, 97-107.
26. Bird AP and Wolffe AP (1999). Methylation-induced repression - belts, braces, and chromatin. Cell 99, 451-454.
27. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, et al. (2002). Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8, 2246-2252.
28. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, and Cairns P (2004). Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64, 6476-6481.
29. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, et al. (2003). OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 34, 337-343.
30. Strathdee G, MacKean MJ, Illand M, and Brown R (1999). A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341.
31. Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, Mita H, Imai K, Tokino T, and Kudo R (2004). Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10, 2000-2006.
32. Fu Y, Campbell EJ, Shepherd TG, and Nachtigal MW (2003). Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 1, 569-576.
33. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, and Koeffler HP (2004). Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 15, 2760-2770.